Mydecine Innovations reports its financial results for fiscal 2021 and updates investors on the company's R&D.
Mydecine Innovations reports its financial results for fiscal 2021 and updates investors on the company's R&D.
Novamind is expanding its psychedelics-based therapies into Brazil via its strategic partner in Latin America, Bienstar Wellness Corp.
Delic Holdings announces two new clinics opening through its subsidiary, Ketmine Wellness Centers (KWC).
Albert Labs announces the filing of a provisional patent application for the production of Psilocybe mycelia and other fungi.
Numinus announces enrolling the first volunteer patient as it hosts a MAPS clinical trial for an MDMA-assisted treatment for PTSD.
Enveric Biosciences announces that it has expanded on its psychedelic drug R&D pipeline along with filing a new patent application.
After strong preclinical testing results, Cybin is looking to advance CYB003 into a Plase 1/2a clinical trial, estimated for mid-2022.
MindMed reports its full-year results for 2021. Progress on major R&D initiatives. Cash balance of $133.5 million.
Novamind announces plans to expand group therapy within its clinical therapy model.
Mydecine reports conditional approval to commence a Phase IIb study on smoking cessation, in partnership with Johns Hopkins University.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now